<?xml version="1.0" encoding="UTF-8"?>
<abstract id="16339220">
  <title>
    <s id="0" section="title">
      Randomised placebo controlled multicentre trial to assess
      <group id="0">
        short  term
        <short>clarithromycin</short>
      </group>
      for patients with stable coronary heart disease : CLARICOR trial .
    </s>
  </title>
  <annotated>
    <s id="5" section="setting">5 Copenhagen University cardiology departments and a coordinating centre .</s>
    <s id="6" section="participants">
      13,702 patients aged 18 to 85 years who had a discharge diagnosis of myocardial infarction or angina pectoris in 1993 -9 and alive in August 1999 were invited by letter ;
      <ps>4373</ps>
      were randomised .
    </s>
    <s id="7" section="interventions">
      <group id="0">
        2  weeks  '  treatment  with
        <short>clarithromycin</short>
        500  mg  /  day
      </group>
      or
      <group id="1">
        matching
        <short>placebo</short>
      </group>
      .
    </s>
    <s id="8" section="main_outcome_measures">
      Primary outcome :
      <outcome id="3">composite  of  all  cause  mortality  ,  myocardial  infarction  ,  or  unstable  angina  pectoris</outcome>
      during
      <time id="0">3  years  '  follow  -  up</time>
      .
    </s>
    <s id="11" section="results">
      <gs group="0">2172</gs>
      participants were randomised to
      <group id="0">clarithromycin</group>
      and
      <gs group="1">2201</gs>
      to
      <group id="1">placebo</group>
      .
    </s>
    <s id="12" section="results">
      We found no significant effects of
      <group id="0">clarithromycin</group>
      on the
      <outcome id="0">primary  outcome</outcome>
      ( hazard ratio 1.15 , 95 % confidence interval 0.99 to 1.34 ) or
      <outcome id="1">secondary  outcome</outcome>
      ( 1.17 , 0.98 to 1.40 ) .
    </s>
  </annotated>
  <fulltext>Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease : CLARICOR trial . To determine if the macrolide clarithromycin affects mortality and cardiovascular morbidity in patients with stable coronary heart disease . Centrally randomised multicentre trial . All parties at all stages were blinded . Analyses were by intention to treat . 5 Copenhagen University cardiology departments and a coordinating centre . 13,702 patients aged 18 to 85 years who had a discharge diagnosis of myocardial infarction or angina pectoris in 1993 -9 and alive in August 1999 were invited by letter ; 4373 were randomised . 2 weeks ' treatment with clarithromycin 500 mg / day or matching placebo . Primary outcome : composite of all cause mortality , myocardial infarction , or unstable angina pectoris during 3 years ' follow - up . Secondary outcome : composite of cardiovascular mortality , myocardial infarction , or unstable angina pectoris . The outcomes were obtained from Danish registers and were blindly assessed by the event committee . 2172 participants were randomised to clarithromycin and 2201 to placebo . We found no significant effects of clarithromycin on the primary outcome ( hazard ratio 1.15 , 95 % confidence interval 0.99 to 1.34 ) or secondary outcome ( 1.17 , 0.98 to 1.40 ) . Mortality was significantly higher in the clarithromycin arm ( 1.27 , 1.03 to 1.54 ; P = 0.03 ) as a result of significantly higher cardiovascular mortality ( 1.45 , 1.09 to 1.92 ; P = 0.01 ) . Short term clarithromycin in patients with stable coronary heart disease may cause significantly higher cardiovascular mortality . The long term safety of clarithromycin in patients with stable ischaemic heart disease should be examined . Trial registration ClinicalTrials .gov NCT00121550 .</fulltext>
  <ignored>
    <s id="1" section="objective">
      To determine if the
      <group id="0">
        macrolide
        <short>clarithromycin</short>
      </group>
      affects
      <outcome id="0">mortality</outcome>
      and
      <outcome id="6">cardiovascular  morbidity</outcome>
      in patients with stable coronary heart disease .
    </s>
    <s id="2" section="design">Centrally randomised multicentre trial .</s>
    <s id="3" section="design">All parties at all stages were blinded .</s>
    <s id="4" section="design">Analyses were by intention to treat .</s>
    <s id="9" section="main_outcome_measures">
      Secondary outcome :
      <outcome id="5">composite  of  cardiovascular  mortality  ,  myocardial  infarction  ,  or  unstable  angina  pectoris</outcome>
      .
    </s>
    <s id="10" section="main_outcome_measures">The outcomes were obtained from Danish registers and were blindly assessed by the event committee .</s>
    <s id="13" section="results">
      <outcome id="0">Mortality</outcome>
      was significantly higher in the
      <group id="0">clarithromycin  arm</group>
      ( 1.27 , 1.03 to 1.54 ; P = 0.03 ) as a result of significantly higher
      <outcome id="4">cardiovascular  mortality</outcome>
      ( 1.45 , 1.09 to 1.92 ; P = 0.01 ) .
    </s>
    <s id="14" section="conclusions">
      <group id="0">
        Short  term
        <short>clarithromycin</short>
      </group>
      in patients with stable coronary heart disease may cause significantly higher
      <outcome id="4">cardiovascular  mortality</outcome>
      .
    </s>
    <s id="15" section="conclusions">
      The long term safety of
      <group id="0">clarithromycin</group>
      in patients with stable ischaemic heart disease should be examined .
    </s>
    <s id="16" section="conclusions">Trial registration ClinicalTrials .gov</s>
    <s id="17" section="conclusions">NCT00121550 .</s>
  </ignored>
</abstract>

